关联交易情况 公司预计与鞍钢集团及其下属企业发生的日常关联交易总金额为412.46亿元，占最近一年度经审计归属 于上市公司股东净资产的347%，交易内容涵盖采购原材料、销售商品等，定价遵循市场化原则。该事 项已通过董事会审议。 重组进展 公司自2023年6月披露资产置换预案后，目前正在对交易方案的可行性与合规性进行审慎论证，因可能 导致关联销售比例大幅增加，事项仍存在不确定性，公司将根据进展及时履行信息披露义务。 经济观察网本钢板材（000761）近期关联交易预计金额巨大，资产置换方案仍在论证，同时公司预告 2025年业绩亏损但同比减亏。 可转债即将到期，公司表示将通过市值管理、降本增效、拓展融资渠道等方式提升上市公司质量，并做 好到期兑付准备。 业绩经营情况 公司已发布业绩预告，预计2025年归属于上市公司股东的净利润亏损38.3亿元，同比减亏23.97%，正式 年报尚待披露。 以上内容基于公开资料整理，不构成投资建议。 可转债终止发行 ...

Group 1 - The core viewpoint of the article is that Zhongke Tongda has released its performance forecast for 2025, expecting a net profit attributable to shareholders to be between -5 million and -3.5 million yuan, indicating a year-on-year reduction in losses by 72.38% to 80.67% due to business structure optimization and effective cost control measures [1] Group 2 - On February 6, 2026, the company's stock price increased by 5.01%, reaching 23.05 yuan per share, with a cumulative increase of 4.28% over three consecutive trading days [1] - The trading volume for the stock was reported at 86.82 million yuan [1]

Group 1: Shareholder Pledge and Control - The controlling shareholder, Guangzheng Investment, has had 9.15 million shares frozen, accounting for 7.08% of its holdings and 1.78% of the company's total share capital. The freeze period is from January 30, 2026, to January 29, 2029. The company states this will not lead to a change in control and will not have a substantial impact on operations [2]. Group 2: Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -5 million and -3 million yuan, indicating a significant reduction in losses of 97.14% to 98.28% compared to a loss of 175 million yuan in the same period of 2024. This improvement is attributed to lean operations in the medical sector, cost control, and a significant reduction in goodwill impairment [3]. Group 3: Related Party Transactions - The company’s board approved a total of up to 15 million yuan for daily related party transactions with Guangzheng Yanyuan Health Management Co., Ltd. and its subsidiaries for the year 2026 [4]. Group 4: Management Changes - A new senior management team has been appointed, including positions such as Vice President, Chief Financial Officer, and Board Secretary, as of December 28, 2025 [5]. Group 5: Business Development - The company has increased its investment in ophthalmology by acquiring, establishing, and holding stakes in multiple ophthalmology-related companies throughout 2025 [6].

Core Viewpoint - The company expects a net loss of 3.83 billion yuan for the year 2025, indicating a reduction in losses compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is projected to be a loss of 3.83 billion yuan, which is a decrease in losses by 2.397 billion yuan compared to the same period last year [1] - The net profit after excluding non-recurring gains and losses is expected to be a loss of 3.92 billion yuan, reflecting a reduction in losses by 2.493 billion yuan year-on-year [1] - The basic earnings per share are projected to be a loss of 0.93 yuan per share [1] Market Conditions - The performance decline is attributed to weak supply and demand in the steel market, price fluctuations, and narrowing price spreads [1] - Despite the company's efforts to enhance competitiveness and reduce losses, it is still expected to report a loss for the entire year [1]

Core Viewpoint - The company anticipates a net profit loss attributable to shareholders of 2.1 billion to 2.7 billion yuan for 2025, a decrease from the previous year's loss of 2.977 billion yuan [1] Financial Performance - The expected net profit loss after deducting non-recurring items is projected to be between 2.25 billion and 2.85 billion yuan, compared to a loss of 4.05 billion yuan in the same period last year [1] - The basic earnings per share are expected to be a loss of 0.49 to 0.63 yuan per share, improving from a loss of 0.69 yuan per share in the previous year [1] Reasons for Performance - The anticipated performance decline is primarily due to the company's proactive adjustment of pricing strategies, leading to impairment signs in certain projects and the need to recognize impairment provisions [1] - The company expects a year-on-year reduction in net profit loss, mainly attributed to an increase in gross margin and investment income compared to the previous year [1]

Core Viewpoint - ST DeRun has announced a forecast for its 2025 fiscal year, expecting a net profit attributable to shareholders to be negative, ranging from -40 million to -25 million yuan, although this represents a significant reduction in losses compared to the previous year's loss of -1.2247585 billion yuan [3]. Group 1 - The company's business operations have developed healthily and orderly during the reporting period, focusing on its core business, strengthening internal management, increasing R&D investment, and expanding market reach, which has led to continuous growth in revenue and profitability [3]. - The exclusion of the former subsidiary Meta System S.p.A. from the consolidated financial statements at the end of 2024 has significantly reduced the negative impact on the company's profits [3]. Group 2 - The company's performance remains under pressure primarily due to the prudent provision for large expected liabilities [4]. - The company received an administrative penalty notice from the Shenzhen Regulatory Bureau of the China Securities Regulatory Commission (CSRC) on December 31, 2025 [4]. - Following the investigation initiated by the CSRC on December 25, 2024, the company has faced multiple lawsuits from investors, leading to significant uncertainty regarding potential compensation amounts, which has negatively impacted the current profit levels due to the full provision for expected liabilities [4].

Core Viewpoint - The company expects to significantly reduce its losses in 2025, with projected net profit attributable to the parent company ranging from -30 million to -45 million yuan, an increase of 144 million to 159 million yuan compared to the previous year [1] Financial Projections - The anticipated net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -34 million and -49 million yuan for 2025 [1] - The company aims for substantial loss reduction in 2025, primarily driven by business expansion, increased sales, and cost reduction efforts [1]

Core Viewpoint - The company expects a significant reduction in net losses for the fiscal year 2025 compared to the previous year, indicating improvements in operational efficiency and sales performance [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between -17.5 million and -12 million yuan, compared to -65.25 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses is expected to be between -25.5 million and -20 million yuan, down from -78.6468 million yuan year-on-year [1] - The basic earnings per share are projected to be between -0.0505 yuan and -0.0346 yuan, compared to -0.1882 yuan per share in the previous year [1] Operational Factors - The improvement in financial performance is attributed to adjustments in the operational plan, enhancements in trade business, and an increase in feed sales [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83 [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the change in performance is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new business which has not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Core Viewpoint - The company expects a net loss of 32 million to 43 million yuan for the fiscal year 2025, a reduction from the previous year's loss of 71.9557 million yuan [1] Group 1 - The anticipated impact of non-recurring gains and losses on net profit for 2025 is estimated to be between 2 million and 3 million yuan [1] - The primary reason for the reduction in losses year-on-year is the completion of the main investment project "YouShu Decision Cloud Brain Project" in 2024, leading to a significant decrease in R&D expenses during the reporting period [1] - The company has further optimized its existing business structure, resulting in growth in revenue and profit during the reporting period [1]